← Leaderboards
Stephanie M Cologna
University Of Illinois At Chicago
$6,486,179
Attributed
$8,923,729
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,743,777 · 6
FDA$1,179,952 · 1
By mechanism
R01$4,304,716 · 2
S10$2,081,999 · 2
U01$1,179,952 · 1
T32$1,006,167 · 1
R24$350,895 · 1
Top collaborators
- Vinay Aakalu5 shared
- Leslie N Aldrich4 shared
- Orly Lazarov3 shared
- Leon Maing Tai3 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Leslie N Aldrich$598,999
Others in their field
Other Emerging Leaders on “Mass Spectrum Analysis”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$25,726,378
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$14,236,023
- Gregory L Hura · University Of Calif-Lawrenc Berkeley Lab$11,347,896
- Jennifer Cohen Price · University Of California, San Francisco$9,197,178
- Danielle L Swaney · University Of California, San Francisco$8,594,269
Research focus
Mass Spectrum AnalysisProteinsLipidsCholesterolFda ApprovedPhenotypeIn VivoNovel TherapeuticsPathway InteractionsLysosomesReportingNpc1 GeneMutationIn VitroEmerging AdultFibroblastsCellsDrug KineticsDrug MetabolismDoseAffectLiverTranslatingBiology
Grant awards (21)
A dual-source ion mobility mass spectrometry system$1,481,999
S10 · FY2025 · OD · contact PI
Novel Therapeutic Approaches for NPC Disease$575,579
R01 · FY2025 · NS · contact PI
Clinically Relevant Biomarkers for Niemann-Pick Type C$393,623
U01 · FY2025 · FD · contact PI
Training program in the biology and translational research on Alzheimer's diseaseand related dementias$333,590
T32 · FY2025 · AG
Novel Therapeutic Approaches for NPC Disease$558,314
R01 · FY2024 · NS · contact PI
Clinically Relevant Biomarkers for Niemann-Pick Type C$386,205
U01 · FY2024 · FD · contact PI
Development of autophagy modulators for evaluation as a therapeutic strategy for Niemann-Pick Type C$385,586
R01 · FY2024 · NS · contact PI
Training program in the biology and translational research on Alzheimer's diseaseand related dementias$341,936
T32 · FY2024 · AG
Novel Therapeutic Approaches for NPC Disease$43,899
R01 · FY2024 · NS · contact PI
Clinically Relevant Biomarkers for Niemann-Pick Type C$16,300
U01 · FY2024 · FD · contact PI
Novel Therapeutic Approaches for NPC Disease$575,579
R01 · FY2023 · NS · contact PI
Development of autophagy modulators for evaluation as a therapeutic strategy for Niemann-Pick Type C$385,586
R01 · FY2023 · NS · contact PI
Clinically Relevant Biomarkers for Niemann-Pick Type C$383,824
U01 · FY2023 · FD · contact PI
Training program in the biology and translational research on Alzheimer's diseaseand related dementias$330,641
T32 · FY2023 · AG
Novel Therapeutic Approaches for NPC Disease$582,175
R01 · FY2022 · NS · contact PI
Development of autophagy modulators for evaluation as a therapeutic strategy for Niemann-Pick Type C$385,586
R01 · FY2022 · NS
Helium Recycling for UIC Nuclear Magnetic Resonance$350,895
R24 · FY2022 · OD · contact PI
Development of autophagy modulators for evaluation as a therapeutic strategy for Niemann-Pick Type C$385,586
R01 · FY2021 · NS
Development of autophagy modulators for evaluation as a therapeutic strategy for Niemann-Pick Type C$41,240
R01 · FY2021 · NS
Development of autophagy modulators for evaluation as a therapeutic strategy for Niemann-Pick Type C$385,586
R01 · FY2020 · NS
Acquisition of a Q-Exactive HF Mass Spectrometer$600,000
S10 · FY2019 · OD · contact PI